Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 551 to 600 of 1327 results for nice quality standards or clinical guidelines

  1. Virtual reality technologies for treating agoraphobia or agoraphobic avoidance: early value assessment (HTG701)

    Early value assessment (EVA) guidance on virtual reality technologies for treating agoraphobia or agoraphobic avoidance.

  2. Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis (TA386)

    Evidence-based recommendations on ruxolitinib (Jakavi). This drug is for adults with disease-related splenomegaly or symptoms caused by primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis, only if they have intermediate-2 or high-risk disease.

  3. DyeVert Systems for reducing the risk of acute kidney injury in coronary and peripheral angiography (HTG594)

    Evidence-based recommendations on DyeVert Systems for reducing the risk of acute kidney injury in coronary and peripheral angiography.

  4. Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer (TA737)

    Evidence-based recommendations on pembrolizumab (Keytruda) with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer in adults.

  5. The NICE public health guidance development process (third edition) (PMG5)

    This manual describes how public health guidance is produced, and explains the stages of guidance development, the different activities, roles and responsibilities of different groups of people involved at different stages

  6. Intravascular lithotripsy for calcified arteries in peripheral arterial disease (HTG707)

    Evidence-based recommendations on intravascular lithotripsy for calcified arteries in peripheral arterial disease. This involves using pressure waves to soften arterial plaque and widen the artery to improve blood flow.

  7. Vortioxetine for treating major depressive episodes (TA367)

    Evidence-based recommendations on vortioxetine (Brintellix) for treating major depressive episodes in adults.

  8. AposHealth for knee osteoarthritis (HTG671)

    Evidence-based recommendations on AposHealth for knee osteoarthritis.

  9. Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies (TA704)

    Evidence-based recommendations on trastuzumab deruxtecan (Enhertu) for treating HER2-positive unresectable or metastatic breast cancer in adults after 2 or more anti-HER2 therapies.

  10. Retaining social workers

    Home Implementing NICE guidance Social care Using NICE guidance in social work: scenarios for principle social workers...

  11. Episcissors-60 for mediolateral episiotomy (HTG538)

    Evidence-based recommendations on Episcissors-60 for mediolateral episiotomy.

  12. Focal therapy using high-intensity focused ultrasound for localised prostate cancer (HTG667)

    Evidence-based recommendations on focal therapy using high-intensity focused ultrasound for localised prostate cancer. This involves using high-intensity focused ultrasound to heat up and destroy only the areas of the prostate with cancer (focal therapy). The aim is to destroy the cancer while reducing damage to healthy prostate tissue.

  13. Experience: Dental services (IND289)

    This indicator covers patient experiences of dental services. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes

  14. Gambling-related harms: identification, assessment and management (NG248)

    This guideline covers identifying, assessing and treating gambling-related harms. This includes people aged 18 and over who are experiencing gambling that harms, and people of any age affected by someone close to them who is experiencing gambling that harms.

  15. Transition between inpatient mental health settings and community or care home settings (NG53)

    This guideline covers the period before, during and after a person is admitted to, and discharged from, a mental health hospital. It aims to help people who use mental health services, and their families and carers, to have a better experience of transition by improving the way it’s planned and carried out.

  16. Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy (TA992)

    Evidence-based recommendations on trastuzumab deruxtecan (Enhertu) for HER2-low metastatic or unresectable breast cancer after chemotherapy in adults.

  17. Percutaneous implantation of pulmonary artery pressure sensors for monitoring treatment of chronic heart failure (HTG599)

    Evidence-based recommendations on percutaneous implantation of pulmonary artery pressure sensors for monitoring treatment of chronic heart failure in adults. This involves putting a small electronic pressure sensor into the pulmonary artery to measure blood pressure.

  18. SEM Scanner 200 for preventing pressure ulcers (HTG556)

    Evidence-based recommendations on SEM Scanner 200 for preventing pressure ulcers.

  19. Lower urinary tract symptoms in men: management (CG97)

    This guideline covers managing lower urinary tract symptoms (LUTS) in men over 18. It aims to improve the quality of life for men with LUTS by recommending which assessments they should receive, and when conservative management, drug treatment and surgery can help.

  20. Investing in line managers

    Home Implementing NICE guidance Social care Using NICE guidance in social work: scenarios for principle social workers...

  21. Sexually transmitted infections: condom distribution schemes (NG68)

    This guideline covers condom distribution schemes. The aim is to reduce the risk of sexually transmitted infections (STIs). In addition, these schemes can provide a good introduction to broader sexual and reproductive health services, especially for younger people, and help prevent unplanned pregnancies.

  22. Supercapsular percutaneously assisted total hip arthroplasty for osteoarthritis (HTG626)

    Evidence-based recommendations on supercapsular percutaneously assisted total hip arthroplasty for osteoarthritis in adults. This involves replacing a hip using smaller cuts than are used in standard surgery.

  23. Trifluridine–tipiracil for previously treated metastatic colorectal cancer (TA405)

    Evidence-based recommendations on trifluridine–tipiracil (Lonsurf) for previously treated metastatic colorectal cancer in adults.

  24. Unintentional injuries on the road: interventions for under 15s (PH31)

    This guideline covers road speed limits, 20 mph zones and engineering measures to reduce speed or make routes safer.

  25. Suspected cancer: recognition and referral (NG12)

    This guideline covers identifying children, young people and adults with symptoms that could be caused by cancer. It outlines appropriate investigations in primary care, and selection of people to refer for a specialist opinion. It aims to help people understand what to expect if they have symptoms that may suggest cancer.

  26. Digital technologies for managing non-specific low back pain: early value assessment (HTG712)

    Early value assessment (EVA) guidance on digital technologies for managing non-specific low back pain in people 16 years and over.

  27. Digital technologies for delivering multidisciplinary weight-management services: early value assessment (HTG700)

    Early value assessment (EVA) guidance on digital technologies for delivering multidisciplinary weight-management services.

  28. Rapid tests for group A streptococcal infections in people with a sore throat (HTG531)

    Evidence-based recommendations on rapid tests for group A streptococcal infections in people aged 5 and over with a sore throat.

  29. Dronedarone for the treatment of non-permanent atrial fibrillation (TA197)

    Evidence-based recommendations on dronedarone (Multaq) for treating non-permanent atrial fibrillation in adults.

  30. Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease (TA223)

    Evidence-based recommendations on cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for treating intermittent claudication in adults with peripheral arterial disease.

  31. Vitamin D: supplement use in specific population groups (PH56)

    This guideline covers vitamin D supplement use. It aims to prevent vitamin D deficiency among specific population groups including infants and children aged under 4, pregnant and breastfeeding women, particularly teenagers and young women, people over 65, people who have low or no exposure to the sun and people with dark skin.

  32. Atrial fibrillation and heart valve disease: self-monitoring coagulation status using point-of-care coagulometers (the CoaguChek XS system) (HTG353)

    Evidence-based recommendations on the CoaguChek XS system for self-monitoring coagulation status in adults and children. The recommendations originally included the InRatio2 PT/INR, but this was withdrawn from the market in October 2016 and is not currently available.

  33. Digital technologies to deliver pulmonary rehabilitation programmes for adults with COPD: early value assessment (HTG718)

    Early value assessment (EVA) guidance on digital technologies to deliver pulmonary rehabilitation programmes for adults with COPD.

  34. Roflumilast for treating chronic obstructive pulmonary disease (TA461)

    Evidence-based recommendations on roflumilast (Daxas) for treating chronic obstructive pulmonary disease in adults with chronic bronchitis.

  35. NICE visualisation of treatment options incorporating technology appraisals: interim process guide (PMG38)

    This process guide explains how treatment option summaries for multiple guidelines were developed in an open, transparent, and timely way, with appropriate expert input

  36. Peristeen Plus transanal irrigation system for managing bowel dysfunction (HTG462)

    Evidence-based recommendations on Peristeen Plus transanal irrigation system for managing bowel dysfunction.

  37. Mepilex Border Heel and Sacrum dressings for preventing pressure ulcers (HTG495)

    Evidence-based recommendations on Mepilex Border Heel and Sacrum dressings for preventing pressure ulcers.

  38. Virtual Touch Quantification to diagnose and monitor liver fibrosis in chronic hepatitis B and C (HTG385)

    Evidence-based recommendations on Virtual Touch Quantification to diagnose and monitor liver fibrosis in chronic hepatitis B and C.

  39. Trabeculectomy with a biodegradable collagen matrix implant for glaucoma (HTG656)

    Evidence-based recommendations on trabeculectomy with a biodegradable collagen matrix implant for glaucoma. This involves cutting a small flap in the white of the eye and putting a patch over the flap to help healing and prevent scarring. Fluid slowly drains out of the flap and the patch dissolves over time. The aim is to reduce pressure in the eye and slow or stop damage to sight.

  40. Panobinostat for treating multiple myeloma after at least 2 previous treatments (TA380)

    Evidence-based recommendations on panobinostat (Farydak) for treating multiple myeloma after at least 2 previous treatments.

  41. HeartFlow FFRCT for estimating fractional flow reserve from coronary CT angiography (HTG429)

    Evidence-based recommendations on HeartFlow FFRCT for estimating fractional flow reserve from coronary CT angiography.

  42. Roxadustat for treating symptomatic anaemia in chronic kidney disease (TA807)

    Evidence-based recommendations on roxadustat (Evrenzo) for treating symptomatic anaemia associated with chronic kidney disease in adults.

  43. Sparsentan for treating primary IgA nephropathy (TA1074)

    Evidence-based recommendations on sparsentan (Filspari) for treating primary immunoglobulin A (IgA) nephropathy in adults.

  44. Artificial intelligence (AI) technologies to aid opportunistic detection of vertebral fragility fractures: early value assessment (HTG760)

    Early value assessment (EVA) guidance on artificial intelligence (AI) technologies to aid opportunistic detection of vertebral fragility fractures.

  45. Omalizumab for previously treated chronic spontaneous urticaria (TA339)

    Evidence-based recommendations on omalizumab (Xolair) for treating severe chronic spontaneous urticaria in people of 12 and over.

  46. Workplace health: long-term sickness absence and capability to work (NG146)

    This guideline covers how to help people return to work after long-term sickness absence, reduce recurring sickness absence, and help prevent people moving from short-term to long-term sickness absence.

  47. NICE decision aid: process guide (PMG42)

    This process guide provides an overview of the key principles used for developing NICE decision aids. It ensures that robust, quality-assured decision aids for people using and providing health and social care services are developed in an open, transparent and timely way, with appropriate input from key groups

  48. Experience: GP services (IND288)

    This indicator covers patient experiences of GP services. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes

  49. Babies, children and young people's experience of healthcare (NG204)

    This guideline describes good patient experience for babies, children and young people, and makes recommendations on how it can be delivered. It aims to make sure that all babies, children and young people using NHS services have the best possible experience of care. It is recognised that parents and carers play a key role, and where appropriate, we took their views into account when developing the recommendations.

  50. Experience: A&E (IND291)

    This indicator covers patient experiences of A&E. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes